Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
Truveta experts: Gestational diabetes screening in real-world practice
Gestational diabetes is one of the most common complications of pregnancy, affecting roughly 5–9% of pregnancies in the United States. When diagnosed and managed early, patients...
Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data
Non–small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases and remains the leading cause of cancer death worldwide. While major advances in targeted therapies...
Johns Hopkins builds research community to explore new frontiers in health using Truveta Data
At Johns Hopkins University, the Hopkins Business of Health Initiative (HBHI) has launched the HBHI–Truveta User Community, dedicated to fostering a collaborative group of...
Impact of the CVS GLP-1 formulary change: Trends in switching
In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the...
Impact of the CVS GLP-1 formulary change: Trends in prescribing
AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025...
One-year cardiovascular outcomes after GLP-1 discontinuation
What happens to cardiovascular health when patients stop taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications? That’s the focus of new research from...
Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)
Biomarker testing has transformed cancer care over the past decade, opening the door to targeted therapies that can improve outcomes for patients with advanced disease. Yet...
Multiple sclerosis: Real-world treatment patterns and outcomes
Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines...
ISPE 2025: Real-world data survival patterns in glioblastoma patients
Authors: Mantas Dmukauskas, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Amy Wu ⊕Truveta, Inc,...